CAPITOL HILL CONSULTING GROUP for NOVARTIS CORPORATION
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
General health care issues related to pharmeuceutical and biological products; Federal Food, Drug and Cosmetic Act (21 USC9); Public Health Service Act (42 USC 6A); follow-on biologics; America's Affordable Health Choices (H.R. 3200); Affordable Healthcare for America Act (H.R. 3962); Patient Protection and Affordable Care Act (H.R. 3590)
| Lobbyist | Covered position, as disclosed |
|---|---|
| BILL K BREWSTER | — |
| STEVEN E IRIZARRY | — |
| DAVID JORY | — |
Medicare/Medicaid MMM
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement; Physician Payments Sunshine Act (S. 301)
| Lobbyist | Covered position, as disclosed |
|---|---|
| BILL K BREWSTER | — |
| STEVEN E IRIZARRY | — |
| DAVID JORY | — |
Government Issues GOV
General patent issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| BILL K BREWSTER | — |
| STEVEN E IRIZARRY | — |
| DAVID JORY | — |
Budget/Appropriations BUD
FDA funding issues, generally; FY 2010 Labor-HHS-Labor Appropriations; FY2010 Supplemental Appropriations; Pandemic vaccine issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| BILL K BREWSTER | — |
| STEVEN E IRIZARRY | — |
| DAVID JORY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.